Wang and coworkers tackled the challenge of ineffective activation of category II TRAIL receptors by soluble agonists using nanoscale hexagonal networks of a cyclic peptide that mimics TRAIL's function on DONs (Figure6a) to induce DR5 clustering by either dimerization of DR5 trimers or trimerization of DR5 dimers, ultimately triggering apoptosis.[25f] The bioactive DONs were tested on breast cancer cell lines with varying sensitivities to TRAIL, namely MDA‐MB‐231, MCF‐7, and SK‐BR‐3. Here, TNFRSF10B is linked to breast cancer.